-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ContraFect Corporation (CFRX) Suffers Falling Market Confidence
ContraFect Corporation (CFRX) Suffers Falling Market Confidence
ContraFect Corporation (NASDAQ: CFRX) is a clinical-stage biotech player which focuses primarily on antibody-based treatments and several strains of protein material as therapy. CFRX stock continues to find itself facing a series of difficult challenges, as hope becomes increasingly thin.
CFRX Takes a Hit Amid News of Potential Delisting
ContraFect Corporation (CFRX) saw its stock price tumble by as much as 8% after day traders worked to pump up the stock in a coordinated rally. The artificial rise came about with no updates on the company and saw a plummeting correction after a news report of a possible delisting from Nasdaq. The company's market capitalization of over $4 million is dangerously low to the minimum floor level of $2.5 million, which would see CFRX taken off the stock exchange, and taken to the OTC markets. The implications of this could potentially be significant to the company, causing an even lower price plunge, and making it difficult for the company to raise funds and finance its development pipeline.
Poor Clinical Data for Contrafect
In another update, CFRX faced growing bearish pressure following its December readout of trial data, which failed to bring confidence to its shareholders. The Exebacase and SoCA arm both showed results that, although higher than the placebo, in the 55 patients of the trial, failed to come up with convincing efficacy statistics. Although the results are not yet complete, the remainder is expected to be revealed to shareholders during the first quarter of 2023. One reason for these results, according to the management links to a "disbalance" in the baseline severity of diabetic-related conditions suffered by patients in the trial.
Conclusion
CFRX stock has been experiencing a mass selloff after the potential Nasdaq delisting notifications stoked new fears among shareholders. There is still hope for a breakthrough with positive trial developments to come to light before the end of FY23Q1.
ContraFect Corporation (NASDAQ: CFRX) is a clinical-stage biotech player which focuses primarily on antibody-based treatments and several strains of protein material as therapy. CFRX stock continues to find itself facing a series of difficult challenges, as hope becomes increasingly thin.
ContraFect Corporation(纳斯达克股票代码:CFRX)是一家临床阶段的生物技术公司,主要专注于基于抗体的治疗和几种蛋白质材料菌株作为疗法。随着希望越来越渺茫,CFRX股票继续面临一系列艰难的挑战。
CFRX Takes a Hit Amid News of Potential Delisting
由于有消息称可能退市,CFRX受到打击
ContraFect Corporation (CFRX) saw its stock price tumble by as much as 8% after day traders worked to pump up the stock in a coordinated rally. The artificial rise came about with no updates on the company and saw a plummeting correction after a news report of a possible delisting from Nasdaq. The company's market capitalization of over $4 million is dangerously low to the minimum floor level of $2.5 million, which would see CFRX taken off the stock exchange, and taken to the OTC markets. The implications of this could potentially be significant to the company, causing an even lower price plunge, and making it difficult for the company to raise funds and finance its development pipeline.
ContraFect Corporation(CFRX)的股价下跌了多达8%,此前日间交易者努力在协调一致的反弹中提振了该股。人为的上涨是在没有公司最新消息的情况下实现的,在有新闻报道称可能从纳斯达克退市之后,出现了暴跌的修正。该公司超过400万美元的市值低得危险地低至250万美元的最低水平,这将使CFRX从证券交易所撤出并进入场外交易市场。这可能会对公司产生重大影响,导致价格进一步下跌,并使公司难以筹集资金并为其开发渠道融资。
Poor Clinical Data for Contrafect
Contrafect 的临床数据不佳
In another update, CFRX faced growing bearish pressure following its December readout of trial data, which failed to bring confidence to its shareholders. The Exebacase and SoCA arm both showed results that, although higher than the placebo, in the 55 patients of the trial, failed to come up with convincing efficacy statistics. Although the results are not yet complete, the remainder is expected to be revealed to shareholders during the first quarter of 2023. One reason for these results, according to the management links to a "disbalance" in the baseline severity of diabetic-related conditions suffered by patients in the trial.
在另一项更新中,CFRX在12月公布试验数据后面临越来越大的看跌压力,但未能给股东带来信心。Exebacase和SoCa组均显示出结果,尽管高于安慰剂,但在试验的55名患者中,未能得出令人信服的疗效统计数据。尽管业绩尚未完成,但其余业绩预计将在2023年第一季度向股东公布。根据管理层的说法,这些结果的原因之一与试验中患者所患糖尿病相关疾病的基线严重程度 “失衡” 有关。
Conclusion
结论
CFRX stock has been experiencing a mass selloff after the potential Nasdaq delisting notifications stoked new fears among shareholders. There is still hope for a breakthrough with positive trial developments to come to light before the end of FY23Q1.
在纳斯达克潜在的退市通知引发了股东的新担忧之后,CFRX股票一直在经历大规模抛售。在 FY23Q1 结束之前,仍有希望取得突破,积极的试验进展会浮出水面。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧